8:08 AM ET
10-Q
Financial Results
Rallybio Q3 2026 Results: Net Loss of $2.73M
Rallybio Corp has announced a proposed merger with Avenzo Therapeutics and continues to report significant losses as a pre-revenue clinical-stage biotechnology company. The company is heavily dependent on the development of its lead candidate, RLYB116, and expects to require substantial additional capital to fund future operations and clinical trials.
- Key figure
- Net loss $2.73M